Pediatric Neurology

Lysogene has announced topline results from its phase 2/3 study evaluating LYS-SAF302, an investigational gene therapy for the treatment of mucopolysaccharidosis type IIIA, or Sanfilippo syndrome.

Daily treatment with risdiplam over 24 months resulted in improved motor function and achievement of developmental motor milestones in infants with type 1 spinal muscular atrophy, according to a study published in The Lancet Neurology.

Low-dose ketamine was generally safe, well-tolerated and effective in treating clinical symptoms in a small group of children with activity-dependent neuroprotective protein syndrome, researchers reported.

Infants born to mothers who had COVID-19 during pregnancy had differences in behavior and movement compared with infants who were unexposed to SARS-CoV-2, preliminary data presented at the European Congress of Psychiatry showed.

SEATTLE — Sarah J. Spence, MD, PhD, shared tips on differentiating pediatric neurological conditions with overlapping symptoms, at the 2022 American Academy of Neurology annual meeting.

Concussion was linked to increased risk for mental health issues, psychiatric hospitalization and self-harm among youths aged 5 to 18 years, according to results of a population-based retrospective cohort study.

Age at pediatric stroke has a significant impact on post-stroke recovery and affects long-term cognitive outcome regardless of lesion size and lesion location, according to results of a cross-sectional study published in Neurology.

Increased sunlight exposure may offer significant protection against development of pediatric MS, according to study results published in Neurology.

Amzell BV, a specialty pharmaceutical development company, announced it has a special protocol assessment agreement with the FDA for a phase 3 trial of its injectable infantile epileptic disease therapy.